Forward looking statements & non-GAAP financial information

This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This presentation contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of the Company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source. For further information, please see the Company’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

Also, this presentation will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Additional information regarding non-GAAP financial measures can be found in the Appendix. Any non-U.S. GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by GAAP, have no standardized meaning prescribed by GAAP and may not be comparable to the calculation of similar measures of other companies.
Our vision

To be the leading partner funding innovation in life sciences

Our mission

We accelerate innovation in life sciences and transform patient lives globally
Royalty Pharma: A unique way to invest in biopharma  
(Nasdaq: RPRX)

<table>
<thead>
<tr>
<th>Market leader and pioneer</th>
<th>Compounding growth through value creation</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>10%+</td>
</tr>
<tr>
<td>years of compounding value</td>
<td>top-line CAGR expected over this decade(2)</td>
</tr>
<tr>
<td></td>
<td>Low-teens</td>
</tr>
<tr>
<td></td>
<td>% average unlevered IRR over multiple decades, high-teens or better with conservative leverage(3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Long duration, diversified portfolio</th>
<th>Significant funding opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>~13 year portfolio duration with track record of growing through royalty expirations</td>
<td>~&gt;1 trillion capital required for biopharma innovation over next decade</td>
</tr>
<tr>
<td>15 blockbusters (&gt;1bn in annual sales) in portfolio(4)</td>
<td>$10-12 billion RP expected capital deployment from 2022-2026; path to double this longer term(5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strong track record</th>
<th>Efficient business model</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of identifying most transformative products</td>
<td>~7-8% cost of capital even with higher rates</td>
</tr>
<tr>
<td>~13% top-line CAGR achieved between 2010-2020</td>
<td>$2.8 billion top-line in 2022 with 92% EBITDA margins, providing consistent and growing cash flow to be redeployed</td>
</tr>
</tbody>
</table>

1. Top-line refers to Royalty Pharma’s Adjusted Cash Receipts  
3. Returns reflect a combination of actual results and estimated projected returns for investments based on analyst consensus sales projections (where applicable). IRR (or returns) are calculated using total cash outflows and total cash inflows, in each case including royalties, milestones and other cash flows. See slide 63 for additional details.  
4. Based on 2022 end market sales and excludes products tied to recently expired royalties.  
5. Royalty Pharma’s capital deployment target provided at Investor Day. See slide 63 for additional details.
Deep network across the biopharma ecosystem

Leading provider of funding solutions for life sciences innovation

Academic institutions
- Emory University
- UCLA
- NYU
- Northwestern University

Non-profits
- Cystic Fibrosis Foundation
- Memorial Sloan Kettering Cancer Center
- The Children's Hospital of Philadelphia
- Massachusetts General Hospital

Small / mid-cap biotechnology
- Biohaven Pharmaceuticals
- Cytokinetics
- Immunomedics
- Biocryst

Global pharmaceuticals
- GSK
- Sanofi
- Pfizer
- AstraZeneca
- Astellas
Clear strategic plan to drive robust and value-enhancing growth

1. **Existing royalties**
   - Acquire existing royalties on market-leading or late-stage development therapies with high commercial potential

2. **Synthetic royalties / R&D funding**
   - Acquire newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential

3. **Launch & development capital\(^{(1)}\)**
   - Additional funding in exchange for long-term payment streams

4. **M&A related**
   - Acquire royalties by facilitating M&A transactions

5. **Adjacencies**
   - Leverage team’s capabilities in business adjacencies

---

1. Including equity investments.
Advancing our partners’ core mission with win-win solutions

<table>
<thead>
<tr>
<th>Structure</th>
<th>Potential benefits to partner</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Existing royalties</strong></td>
<td>• Diversification of asset portfolio</td>
</tr>
<tr>
<td></td>
<td>• Non-dilutive funding for business growth and investment</td>
</tr>
<tr>
<td></td>
<td>• Upfront capital today in exchange for a long-dated stream of payments</td>
</tr>
<tr>
<td><strong>Synthetic royalties</strong></td>
<td>• Funding for completion of development and commercialization of portfolio</td>
</tr>
<tr>
<td></td>
<td>• Retain operational control of development programs</td>
</tr>
<tr>
<td></td>
<td>• Lower cost of capital than issuing equity</td>
</tr>
<tr>
<td><strong>Launch &amp; development capital</strong></td>
<td>• Launch funding offers flexible, patient, long-term alternative financing</td>
</tr>
<tr>
<td></td>
<td>• Lower cost of capital than selling equity and less restrictive than debt</td>
</tr>
<tr>
<td><strong>M&amp;A</strong></td>
<td>• Monetize non-strategic passive royalties to reduce net M&amp;A price</td>
</tr>
<tr>
<td></td>
<td>• Capital provided through purchase of royalties and supplemental funding</td>
</tr>
</tbody>
</table>
Simple and efficient business model focused on cash flow

1. See slide 63 for definitions. Refer to the Appendix for a GAAP to non-GAAP reconciliation.
Highly efficient business model generates significant cash flow

Overview of 2022 non-GAAP metrics\(^{(1)}\)

<table>
<thead>
<tr>
<th>$ in millions (except per share amount)</th>
<th>FY 2022</th>
<th>YoY growth (%)</th>
<th>% ACR(^{(1)})</th>
<th>Commentary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Royalty receipts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distributions to non-controlling interests</td>
<td></td>
<td></td>
<td></td>
<td>Payments to legacy investors related to pre-IPO investments; declining % over time(^{(2)})</td>
</tr>
<tr>
<td>Adjusted Cash Receipts (non-GAAP)</td>
<td>2,789</td>
<td>31%</td>
<td>8.0%</td>
<td>“top-line”</td>
</tr>
<tr>
<td>Payments for operating and professional costs</td>
<td>-223</td>
<td></td>
<td></td>
<td>“G&amp;A” expected to remain relatively constant as % of ACR(^{(1)})</td>
</tr>
<tr>
<td>Adjusted EBITDA (non-GAAP)</td>
<td>2,566</td>
<td>32%</td>
<td>92.0%</td>
<td></td>
</tr>
<tr>
<td>Interest paid and other expenses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development-stage funding payments – ongoing</td>
<td>-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development-stage funding payments – upfront &amp; milestones</td>
<td>-175</td>
<td></td>
<td></td>
<td>Reflects payments classified as R&amp;D to align with industry non-GAAP modification</td>
</tr>
<tr>
<td>Adjusted Cash Flow (non-GAAP)</td>
<td>2,235</td>
<td>42%</td>
<td>80.1%</td>
<td>“bottom-line”</td>
</tr>
</tbody>
</table>

3,231
-442
2,789
-223
2,566
-154
2,235
-175

3.68 / share\(^{(3)}\)

---

1. See slide 63 for definitions. Refer to the Appendix for a GAAP to non-GAAP reconciliation.
2. There is no non-controlling interest related to post-IPO investments.
Track record of delivering strong growth

Adjusted Cash Receipts\(^{(1)}\)

- 2012: $1.05bn
- 2022: $2.79bn
- Adjusted Cash Receipts for periods 2020 and earlier are pro forma for current non-controlling interests. See slide 63 for additional information.

Capital deployed (annual average)

- 2012-2016: $1.49bn
- 2017-2022: $2.17bn
- +45%
Innovative business model supports biopharma ecosystem

**Fund Structure 1996 to 2003**
- Funded only with equity
- Achieved proof-of-concept
- Focused on 3rd party royalties in approved products

**Ongoing Business 2004 to 2011**
- Lowered cost of capital with leverage
- Expanded to M&A related royalties

**Ongoing Business 2012 to 2020**
- Development stage products
- Created synthetic royalties
- Added supplemental funding
- Grew team and scaled business

**Public Company (IPO) in June 2020 Inaugural Bond Issuance in August 2020(1)**
- Significantly scale business
- Selectively add adjacencies

**Increased share of >$3 trillion market opportunity**

**Capital Deployed**
- ~$5bn
- ~$14bn
- ~$300m
- ~$9bn

**Source:** Internal estimates. Data reflects actual cash deployed for transactions.
1. Aggregate of $6.0 billion senior unsecured notes with weighted-average maturity of approximately 12.5 years and weighted-average coupon of 2.125%.
Strong competitive moat in biopharma royalty funding

**Business model**
- Publicly traded company
- Long royalty durations
- ~7-8% cost of capital
- ~2.5% cost of debt\(^1\)

**Scale**
- Portfolio >45 products
- Large investment capacity
- Deep capital markets access
- Ability to leverage portfolio

**Platform**
- Long-tenured team
- Singular biopharma focus
- Long collaboration history
- Deep industry relationships
- Partner of choice

**Other Royalty Buyers**
- Serial fund structures
- Often shorter royalty durations
- High-single to double-digit cost of capital

1. Weighted average coupon.
Powerful engine for value creation and compounding growth

Consistently replenishing portfolio, powering long-term compounding growth
Impressive track record of strong top-line growth since IPO

Adjusted Cash Receipts

(year/year growth)

1. “Top-line” refers to Royalty Pharma’s Adjusted Cash Receipts. See slide 63 for definitions.
2. On pro forma basis. See slide 63 for definition and additional information.
3. Growth of 12% is prior to the $458m accelerated Biohaven redemption payment received in Q4 2022.
4. Growth of 11% is prior to the $475m Zavzpret milestone payment received in Q1 2023 and $13m Series A Biohaven Preferred Shares redemption payment received in Q1 2022.
5. Growth is prior to the $13m Series A Biohaven Preferred Shares redemption payment received in each of the respective year ago quarters.
## Significant accomplishments since IPO

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th></th>
<th>Today</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Growth</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted Cash Receipts$^{(1)}</td>
<td>$1.8bn</td>
<td>$2.5bn / $3.0bn</td>
<td>~40% / ~65%</td>
<td></td>
</tr>
<tr>
<td>2020-2025 ACR CAGR outlook$^{(2)}</td>
<td>6-9%</td>
<td>11-14%</td>
<td>&gt;65%</td>
<td></td>
</tr>
<tr>
<td><strong>Capital deployment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Announced deal value (prior 3 years)</td>
<td>$3.7bn</td>
<td>$11bn</td>
<td>~3x</td>
<td></td>
</tr>
<tr>
<td>5-year capital deployment target$^{(3)}</td>
<td>&gt;$7bn</td>
<td>$10-12bn</td>
<td>&gt;55%</td>
<td></td>
</tr>
<tr>
<td><strong>Portfolio</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New therapies added (prior 3 years)</td>
<td>14</td>
<td>23</td>
<td>~65%</td>
<td></td>
</tr>
<tr>
<td>Development-stage therapies$^{(4)}</td>
<td>3</td>
<td>11</td>
<td>3.7x</td>
<td></td>
</tr>
<tr>
<td><strong>Platform</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full time employees$^{(5)}</td>
<td>35</td>
<td>91</td>
<td>&gt;2.5x</td>
<td></td>
</tr>
<tr>
<td>In-depth opportunity reviews$^{(6)}</td>
<td>50</td>
<td>70</td>
<td>40%</td>
<td></td>
</tr>
</tbody>
</table>

ACR: Adjusted Cash Receipts

1. See slide 63 for definitions. Adjusted Cash Receipts of $1.8 billion is for the period ended December 31, 2020 and ~$2.5 billion is based off the midpoint of 2023 guidance of between $2,950 and $3,000 million and excludes the $475 million Zavzpret milestone payment. The 2020-2025 Adjusted Cash Receipts CAGR of 6-9% was provided on August 12, 2020. The 2020-2025 Adjusted Cash Receipts CAGR of 11-14% was provided at May 17, 2022 Investor Day. The increase is calculated using the midpoint of each of the ACR outlook ranges. See slide 63 for factors that may impact our outlook. Capital deployment target of >$7bn provided on August 12, 2020. Capital deployment target of $10-12bn provided at May 17, 2022 Investor Day. See slide 63 for factors that may impact our capital deployment target. The increase is calculated using the midpoint of today’s 5-year capital deployment target range.

2. The 2020-2025 Adjusted Cash Receipts CAGR of 6-9% was provided on August 12, 2020. The 2020-2025 Adjusted Cash Receipts CAGR of 11-14% was provided at May 17, 2022 Investor Day. The increase is calculated using the midpoint of each of the ACR outlook ranges. See slide 63 for factors that may impact our outlook.

3. Full time employees of our Manager for the 2020 period is as of December 31, 2019; full time employees of our Manager for the today period is as of November 2023.

4. Development-stage therapies for 2020 period is as of November 2020; development-stage therapies for the today period is as of November 2023.

5. Capital deployment target of >$7bn provided on August 12, 2020. Capital deployment target of $10-12bn provided at May 17, 2022 Investor Day. See slide 63 for factors that may impact our capital deployment target. The increase is calculated using the midpoint of today’s 5-year capital deployment target range. In-depth opportunity reviews of 50 is for the period ended December 31, 2020 and 70 is for the period ended December 31, 2022.
Industry fragmentation and complexity drive royalty creation

Academia / non-profit
(>5,000 labs)

Biotechs
(>8,000 companies)

Large Pharma
(~25 companies)

Synthetic royalties

License
Royalties
License
Royalties
License & Partner, M&A

L&D: launch & development capital
Significant opportunity to fund biopharma innovation

Biopharma ecosystem cumulative R&D spend over next decade

- >$1 trillion by academic, non-profits
- >$2 trillion by profitable biopharmas
- Synthetic royalties
- Third-party royalties
- Synthetic royalties, launch & development capital

Global pharma market

- >$2 trillion Biopharma revenues (2032e)

Entire biopharma ecosystem drives our pipeline

Source: Bloomberg, Visible Alpha and CapIQ
1. Based on estimates from Research America and internal Royalty Pharma analysis.
2. Based on Evaluate Pharma as of May 2022.
Strong momentum for biopharma royalty market

Biopharma royalty market growth\(^{(1)}\)

**Number of transactions**

- 2015: 4
- 2016: 7
- 2017: 15
- 2018: 13
- 2019: 18
- 2020: 22
- 2021: 24
- 2022: 27

**Dollar value of transactions** ($ in billions)

- 2015: 0.6
- 2016: 2.2
- 2017: 4.6
- 2018: 1.7
- 2019: 4.3
- 2020: 5.6
- 2021: 5.3
- 2022: 6.2

Royalty Pharma represented >50% of transaction value and >1/4 of transaction volume in 2022

---

1. Internal estimates of historical biopharma royalty market size based on announced transactions.
Royalty Pharma is the leader in royalty transactions

Biopharma royalty market size and share by transaction value, 2012-2023 YTD\(^{(1)}\)

Royalty Pharma has maintained ~60% overall share since 2012 and is the go-to partner for larger transactions

1. Internal estimates of historical biopharma royalty market size based on announced transactions; size of blocks are relative to total announced value in each deal size range.
Long duration portfolio consistently replenished

Duration of portfolio (At IPO)

Beyond 2030

~70%

Duration of royalties acquired 2020-2023 YTD (Today)

Beyond 2030

~95%

Duration of portfolio (Today)

Beyond 2030

~90%

~13 year weighted average royalty portfolio duration
1. Recent transactions includes 2020, 2021, 2022 and 2023 transactions.

2. Consensus sales sourced from Visible Alpha as of November 2023 and includes therapies with consensus available at the time of the deal and now.

3. Change in Evrysdi consensus sales is from date of initial PTC transaction (July 20, 2020).

4. Change in Orladeyo consensus sales is from date of initial BioCryst transaction (December 7, 2020).

Industry leading exposure to blockbuster products

Portfolio includes premier products and franchises backed by strong support from marketers

Peers consist of Eli Lilly, Johnson & Johnson, Merck, Pfizer, AbbVie, Bristol Myers Squibb, Gilead, Amgen, Biogen, Vertex, Regeneron, Roche, Novartis, GSK, Sanofi, Novo Nordisk and AstraZeneca.

1. Calculated based on 2022 end market sales and excludes products tied to recently expired royalties.
Unique ability to invest in multiple products in the same class

- Lipoprotein(a)
  - olpasiran
  - pelacarsen

- Spinal Muscular Atrophy
  - Evrysdi
  - SPINRAZA

- Prostate cancer
  - Erleada
  - Xtandi

- HIV
  - BIKTARVY
  - Truvada
  - PREZISTA

- Anti-TNFs
  - HUMIRA
  - Remicade
  - CIMZIA

- Multiple sclerosis
  - TYSABRI
  - Tecfidera

- Migraine
  - Emgality
  - Nurtec ODT

- Schizophrenia
  - KarXT
  - MK-8189

Portfolio agnostic to therapeutic area, modality and drug class
Participating in most important waves of biopharma innovation

Next exciting waves of biopharma innovation

- **Trikafta** - cystic fibrosis
- **Tremfya** - immunology
- **Cabometyx** - kidney cancer
- **Entyvio** - gastrointestinal
- **Evrysdi** - spinal muscular atrophy
- **Nurtec/Emgality** - migraine

**Rituxan** - blood cancer/immunology
**Neupogen/Neulasta** - supportive cancer care
**Thalomid** - blood cancer

**Truvada** - HIV
**Humira** - immunology
**Remicade** - immunology
**Lyrica** - nerve pain

**Januvia** - diabetes
**Tecfidera/Tysabri** - MS
**Imbruvica** - blood cancer
**Kalydeco** - cystic fibrosis
**Xtandi** - prostate cancer
Synthetic royalty opportunity is underutilized

- Synthetic royalties – an important innovation with significant growth potential
- Multiple potential benefits
  - Innovator retains operational control
  - Capital at scale
  - Program and product specific
  - Lower cost of capital vs. equity
  - Non-dilutive to equity and preserves equity upside
  - Flexible and creative structuring
  - Independent validation of opportunity
  - Preserves attractiveness to strategic acquirer

Source: Dealogic, Biomedtracker, internal estimates, Evaluate.
1. Includes capital raised through initial public offerings (IPOs), follow-on offerings, equity linked issuances and upfronts from licensing deals.
2. Royalty funding includes upfront investment consideration, including acquisitions of synthetic royalties and associated equity investments.

Synthetic royalties represented only ~2% of biopharma funding over past 5 years

~$260bn biopharma industry funding, 2018-2022

[Diagram showing funding sources: Synthetic royalties, Licensing deals (upfront), IPOs, Convertible Debt, Follow-on equity offerings]
Synthetic royalty market has room for significant growth

Source: Dealogic, Biomedtracker, internal estimates, Evaluate.

1. Includes capital raised through initial public offerings (IPOs), follow-on offerings, equity linked issuances and upfrons from licensing deals.
2. Royalty funding includes upfront investment consideration, including acquisitions of synthetic royalties and associated equity investments.
3. Estimated capital needs for today’s unprofitable biopharmas based on Visible Alpha, Dealogic, internal estimates.

---

**Biopharma funding sources**

(2018 to 2022)

- Total capital: ~$260bn
- Synthetic royalties: ~$4bn
- Estimated capital needs for today’s unprofitable biopharmas based on 2% penetration.

**Synthetic royalty opportunity**

(Cumulative next 5 years)

- Total capital: >$450bn
- Synthetic royalties: ~$18bn
- Illustrative synthetic royalty penetration rates (Royalty Pharma + others): 4% and 8%.

Opportunity to capture significant share of this growing market.
### Providing needed capital for M&A transactions

<table>
<thead>
<tr>
<th>Challenge</th>
<th>Mid-cap M&amp;A</th>
<th>Large pharma M&amp;A</th>
<th>Divestitures</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cash flow constraints historically have meant equity is the primary funding source</td>
<td>Non-strategic assets at target companies may significantly increase acquisition price</td>
<td>Increasing FTC scrutiny of M&amp;A transactions may reduce attractiveness of target due to regulatory concerns</td>
</tr>
<tr>
<td>Our solution</td>
<td>Enable delivery of cash through synthetic royalty creation, third-party royalty monetization and/or launch and development capital</td>
<td>Reduce net price of acquisition by monetizing non-strategic royalty assets at target companies acquired by large pharma</td>
<td>Finance the acquisition of assets that must be divested due to anti-trust concerns</td>
</tr>
<tr>
<td>Examples</td>
<td><img src="morphosys.png" alt="morphosys" />, <img src="constellation.png" alt="constellation" /></td>
<td><img src="astellas.png" alt="astellas" /></td>
<td>Emerging opportunity</td>
</tr>
</tbody>
</table>

**FTC:** Federal Trade Commission
Emerging funding paradigm for successful biotechs

**Immunomedics raised ~$1.9bn in capital**(1)

- Royalty Pharma Partnership: 13%
- Debt: 60%
- Equity: 23%
- Other: 4%

Acquired by Gilead for ~$21bn
1.7x CoC return to date + future royalties

**Biohaven raised ~$3.2bn in capital**(2)

- Royalty Pharma Partnership: 26%
- Pfizer partnership: 35%
- Debt: 23%
- Equity: 16%
- Other: 2%

Acquired by Pfizer for ~$12bn
1.8x CoC expected return + future royalties

**Cytokinetics raised ~$2.5bn in capital**(3)

- Royalty Pharma Partnership: 22%
- Debt: 28%
- Equity: 23%
- Other: 27%

**BioCryst raised ~$1.8bn in capital**(4)

- Royalty Pharma Partnership: 19%
- Debt: 44%
- Equity: 28%
- Other: 10%

CoC: cash on cash

Note: estimates based on publicly available information as of date of announced transaction. Debt and Royalty Pharma partnerships assume fully drawn facilities and maximum transaction value. Other primarily includes upfront payments. Biohaven CoC return includes expected receipt of $475 million zavegepant milestone in the first half of 2023.

1. Capital raised since January 1, 2013. 2. Capital raised since Biohaven’s May 2017 IPO. Only includes upfront payment from Pfizer partnership. 3. Capital raised since Cytokinetics expanded license agreement with Amgen, June 12, 2013. 4. Capital raised since BioCryst’s December 2012 corporate restructuring to focus strategy on advancing hereditary angioedema program.
Proprietary sourcing provides competitive advantage

Source of deals\(^{(1)}\)

- **Pharma M&A**
  - Bilateral: 60%
  - Limited process\(^{(2)}\): 23%
  - Auction: 18%

- **Royalty Pharma**
  - Bilateral: 32%
  - Limited process\(^{(2)}\): 16%
  - Auction: 51%

**Majority of Royalty Pharma transactions negotiated on a bilateral basis**

- Network of deep relationships
- Track record of “win-win” outcomes
- Scale advantages
- Strong record of value-enhancing acquisitions

---

1. Includes all Royalty Pharma transactions announced from January 2016 to March 2023; analysis of Schedule 14D-9s for pharma M&A transactions and includes biotech acquisitions greater than $1 billion in value (57 in total). Percentages are based on number of transactions.
2. Limited process is three or fewer parties involved in process.
Unique Research & Investments team and process

- Pioneering the royalty market for 25+ years
  - Innovating new funding solutions, including synthetic royalties

- One Royalty Pharma team at the center of every transaction
  - Long-tenured expert team with deep scientific experience

- Open business model: tailored solutions and true partnerships
  - Proud of partnerships that grow over multiple transactions

- Platform built to scale with the royalty market
  - Team and process growing to address the large opportunity ahead

- Exhaustive diligence process sharpened over decades
  - Able to integrate and interpret a broad and expanding information set

- Leveraging big data through Strategy & Analytics
  - Unique platform for clinical trial analysis and market evaluation
Our framework focuses on key product success factors

- Strong scientific rationale
- Significant impact on patients and/or caregivers
- Conviction in probability of clinical and regulatory success for pre-approval programs
- Mission and execution-oriented management team
- Strong marketer and global commercial opportunity
- Clear commercial positioning
- Potential for multiple indications or label expansion
- First-in-class or best-in-class
- Long duration of patent protection or exclusivity
- Compelling value proposition for government and commercial payors
One Royalty Pharma team at the center of every transaction

Traditional business development

- Business Development
- R&D
- Commercial
- Legal
- Corporate M&A

- Identify & develop
- Diligence
- Structure & negotiate
- Execute

Decision maker

CEO / CFO or Committee

Transaction decision

• Siloed due diligence
• Layered decision making
• Reduced accountability

Royalty Pharma process

- Royalty Pharma Deal Team
  - Executive leadership
  - Research & Investments\(^1\)
  - Legal

- Unified decision making

- Identify & develop
- Diligence
- Structure & negotiate
- Execute

Royalty transaction

- Market/product knowledge
- Integrated decision making
- Ownership and accountability
- High conviction investments

---

1. Includes Research & Investments, Investments & Capital Strategies and Strategy & Analytics.
Extensive due diligence process sharpened over decades

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Regulatory, IP, Manufacturing</th>
<th>Commercial</th>
<th>Contracts, Governance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physician diligence</strong></td>
<td><strong>Intellectual property</strong></td>
<td><strong>Claims analysis</strong></td>
<td><strong>Transaction</strong></td>
</tr>
<tr>
<td>• US/EU/Japan</td>
<td>• US/EU/Japan and other</td>
<td>• Patient diagnosis, treatment, compliance</td>
<td>• Accounting treatment</td>
</tr>
<tr>
<td>• KOL/academic</td>
<td>• Pharmacokinetics</td>
<td>• Site of care</td>
<td>• Tax implications</td>
</tr>
<tr>
<td>• Community</td>
<td>• Pharmacodynamics</td>
<td>• Other patient metrics</td>
<td><strong>Licensing and contracts</strong></td>
</tr>
<tr>
<td>• Surveys</td>
<td>• Dose modeling</td>
<td></td>
<td>• Analysis of contract language</td>
</tr>
<tr>
<td><strong>Statistics</strong></td>
<td><strong>Manufacturing</strong></td>
<td><strong>Market sizing</strong></td>
<td><strong>Risk assessment</strong></td>
</tr>
<tr>
<td>• Probability of success</td>
<td>• Modality expertise: small molecule, biologics, gene therapy</td>
<td>• Patient finding</td>
<td><strong>Expert structuring and drafting</strong></td>
</tr>
<tr>
<td>• Effect size modeling</td>
<td>• Regulatory perspectives</td>
<td>• Claims-driven</td>
<td><strong>Management &amp; governance</strong></td>
</tr>
<tr>
<td>• Enrollment modeling</td>
<td>• Capacity planning</td>
<td>• Epidemiology</td>
<td>• Experience and strategy</td>
</tr>
<tr>
<td>• Statistical Analysis Plans</td>
<td></td>
<td>• Scaled market surveys</td>
<td>• Compensation alignment</td>
</tr>
<tr>
<td><strong>Drug delivery</strong></td>
<td><strong>US pricing</strong></td>
<td><strong>Payors</strong></td>
<td><strong>Environmental, Social &amp; Governance</strong></td>
</tr>
<tr>
<td>• Auto-injectors and devices</td>
<td>• Pricing modeling</td>
<td>• Payor/PBM executives</td>
<td>• Board oversight</td>
</tr>
<tr>
<td>• Design and human factors</td>
<td>• Gross-to-net modeling</td>
<td>• Formulary analyses</td>
<td>• ESG-informed investment processes</td>
</tr>
<tr>
<td>• Formulation technologies</td>
<td></td>
<td></td>
<td><strong>Commercial strategy</strong></td>
</tr>
<tr>
<td><strong>Regulatory</strong></td>
<td><strong>Competition</strong></td>
<td><strong>International access</strong></td>
<td>• Interview sales and marketing executives, MSLs and district managers</td>
</tr>
<tr>
<td>• US/FDA meeting minutes</td>
<td>• Landscape analysis</td>
<td>• Market-by-market pricing</td>
<td>• Required promotional spend</td>
</tr>
<tr>
<td>• EU/EMA meeting minutes</td>
<td>• Product profile and cost comparisons</td>
<td>• Addressable patients</td>
<td></td>
</tr>
</tbody>
</table>
Leveraging the best internal and external expertise available

Internal team\(^{(1)}\) (# of employees)

<table>
<thead>
<tr>
<th>Company</th>
<th># of employees</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTC Therapeutics</td>
<td>4</td>
</tr>
<tr>
<td>Evrysdi</td>
<td>9</td>
</tr>
<tr>
<td>Cytokine</td>
<td>7</td>
</tr>
<tr>
<td>aficamten</td>
<td>4</td>
</tr>
<tr>
<td>morphosys Tremfy`</td>
<td>7</td>
</tr>
<tr>
<td>bio cryst orladeyo BCX9930</td>
<td>4</td>
</tr>
<tr>
<td>Paused project (did not transact)</td>
<td>4</td>
</tr>
</tbody>
</table>

~18x average multiplier

External support (# of experts)

<table>
<thead>
<tr>
<th># of experts</th>
</tr>
</thead>
<tbody>
<tr>
<td>86</td>
</tr>
<tr>
<td>49</td>
</tr>
<tr>
<td>87</td>
</tr>
<tr>
<td>77</td>
</tr>
<tr>
<td>129</td>
</tr>
</tbody>
</table>

Amplifying our team with the best external advice available to drive high conviction investments

1. Internal team represents Senior Vice Presidents (SVPs) and below in Research & Investments, Legal, Strategy & Analytics and other departments.
Our ambitious vision for Strategy & Analytics

**Strategic search and evaluation**
- Horizon scanning to position Royalty Pharma for the future
  - Identify emerging target companies and products
  - Enhance knowledge of pipelines and mechanisms in development
  - Perform clinical trial analysis and competitive intelligence
  - Stay ahead of faster biopharma innovation cycles
- Earlier partner engagement benefits business development

**Data and analytics**
- Unique insight from proprietary integration of data sources
  - Automation to ensure full coverage at scale
- Best-in-class platform for market evaluation and forecasting
  - Patient mapping – diagnosis, procedures and treatment
  - Long-term ambition to develop for global markets

Strategy & Analytics improves Royalty Pharma’s investment process and adds value to our partners
On track to meet or exceed 5-year capital deployment target

Transactions announced in 2022 and 2023

5-year capital deployment target\(^{(1,2)}\)
(Announced value, since January 1, 2022)

1. See slide 63 for factors that may impact our capital deployment target.
2. Capital deployment target provided at May 17, 2022 Investor Day.
Announced $3.5 billion of transactions in 2022

2022 Royalty Pharma investment activity

- >350 initial reviews
- 106 CDAs signed
- 70 in-depth reviews
- 38 proposals submitted
- Executed 9 transactions for $3.5bn\(^{(1)}\)

Maintained strong financial discipline: ~3% of initial reviews resulted in a transaction

---

1. Data reflects total announced transaction value in 2022 ($2.0 billion of total is upfront) and includes Epizyme and Biohaven equity transactions.
Positive market backdrop supports strong pipeline trends

Strong growth in initial reviews
- Initial reviews
- Pre-IPO: >200, >265, >300, >350
- 2019-2022 increase: +75%

Opportunity set increasing
- In-depth reviews
- 2019-2022 increase: +75%

Robust acquisition activity
- Pre-IPO: 2019: $2.2bn, 2020: $2.4bn, 2021: $3.0bn, 2022: $3.5bn
- 2019-2022 increase: +58%
Acquired approved and development-stage royalties

**Approved Products**

- Predictable and de-risked cash flows
- Growth from increased penetration
- Additional upside from new indications / geographies

**Development-Stage Products**

- Broad landscape of opportunities
- Require strong proof-of-concept data
- Significant upside potential

---

**Total - ~$22.7bn**

- Approved Products ~$14.0bn, 62%
- Development-Stage Products ~$8.7bn, 38%

**~$6.6bn or 77% of Development-Stage Product Acquisitions Are Now Approved**

**Current Status**

- Approved Products ~$20.7bn, 91%
- Development-Stage Products ~$1bn, 5%
- Not Approved ~$1bn, 4% (2)

---

2. Not approved includes investments in omecamtiv, gantenerumab, stilimumab, BCX9930, vosaroxin, palbociclib and Merck’s anti-IL17 nanobody M1095.
Healthy mix of approved and development-stage therapies

~$22.7 billion in cumulative capital deployed
($ in billions)

Annual capital deployment

Capital deployed balanced on average across approved and development-stage therapies with some annual variability.
Capital allocation strategy to drive shareholder value creation

$20 billion in projected 2022-2026 capacity to reinvest and return to shareholders

Royalty acquisitions

$10-$12bn 5-year target\(^{(1)}\)
- Announced ~$7.3bn since 2022 (~$4.2bn deployed upfront)
- Robust and active transaction pipeline
- Largely self-funded over time via retained cash flow

Additional Capacity

Royalty investments prioritized
- >$4bn capacity with conservative leverage
- Committed to investment grade credit rating

Share repurchases

Up to $1bn (announced March 2023)
- Received shareholder approval at AGM in June 2022
- Repurchased ~10 million shares for $305m through November 7, 2023
- Authorization valid through June 2027

Dividends

~3% annual yield
- Current dividend of $0.20/quarter
- Commitment to the dividend

AGM: Annual General Meeting
1. 5-year capital deployment target provided at May 2022 Investor Day.
2. Cumulative 5-year capacity includes cash generated from operations, future acquisitions and debt capacity. Figure provided at May 2022 Investor Day.
Consistently attractive returns amplified by conservative leverage

**Royalty Pharma returns**

- **Target**
  - High-Single to Low-Double-Digit %
  - Teens %
  - Low Teens % Average Returns

- **Estimated**
  - Deals from 2012-2023

- **Unlevered returns**

- **Approved royalties**

- **Unapproved royalties**

**Leverage benefit to return profile**

- **Based on investment periods since 2012 (%)**
- **Estimated cost of capital**

- **Low Teens Blended %**

- **Roughly ~1/3 of royalty acquisitions funded with low-cost debt**

**Proven track record of consistent returns, amplified with conservative leverage, creating value in excess of cost of capital**

1. Illustrative returns reflect a combination of actual results and estimated projected returns for investments from 2012 – Q3 2023 based on analyst consensus sales projections (where applicable). IRR (or returns) are calculated using total cash outflows and total cash inflows, in each case including royalties, milestones and other cash flows.
What does $1bn of investment mean for future top-line?

Representative annual Adjusted Cash Receipts\(^{(1,2)}\) ("top-line") from $1bn of investment - based on blend of historical acquisitions
(As of May 2022 Investor Day)

<table>
<thead>
<tr>
<th>Years Post Acquisition</th>
<th>Representative Annual Adjusted Cash Receipts</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>$0m</td>
</tr>
<tr>
<td>1</td>
<td>$160-180m</td>
</tr>
<tr>
<td>2</td>
<td>$160-200m</td>
</tr>
<tr>
<td>3</td>
<td>Period of accelerated growth during product launch</td>
</tr>
<tr>
<td>4</td>
<td>Period of reduced growth in latter-half of decade post product launch</td>
</tr>
<tr>
<td>5</td>
<td>Often significant residual “tail” beyond 10 years</td>
</tr>
<tr>
<td>10</td>
<td>$160-200m</td>
</tr>
<tr>
<td>15</td>
<td>$0m</td>
</tr>
</tbody>
</table>

1. See slide 63 for definitions and factors that may impact the achievement of our growth outlook.
2. Representative cash receipts based on blended average of actual and projected returns for approved and development-stage transactions over the last five years under a range of scenarios.
### CF to remain important contributor regardless of triple scenario

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Components</th>
<th>Triple Combination</th>
<th>2030 Franchise Sales</th>
<th>2030 ACR from CF</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status quo</strong></td>
<td>elexaftor</td>
<td>ivacaftor</td>
<td>~9%</td>
<td>~$11.5bn</td>
<td>2037</td>
</tr>
<tr>
<td></td>
<td>tezacaftor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>New CF Triple</strong></td>
<td>vanzacaftor</td>
<td>deuterated ivacaftor</td>
<td>~8%</td>
<td>~$900-950m</td>
<td>2039-2041</td>
</tr>
<tr>
<td>(deuterated ivacaftor is royalty bearing)</td>
<td>tezacaftor</td>
<td></td>
<td></td>
<td>+$0-$50m vs status quo</td>
<td></td>
</tr>
<tr>
<td><strong>New CF Triple</strong></td>
<td>vanzacaftor</td>
<td>deuterated ivacaftor</td>
<td>~4%</td>
<td>~$600-700m</td>
<td></td>
</tr>
<tr>
<td>(deuterated ivacaftor not royalty bearing)</td>
<td>tezacaftor</td>
<td></td>
<td></td>
<td>-$200-$300m vs status quo</td>
<td></td>
</tr>
</tbody>
</table>

**Upside Drivers:**
- ~6,000 discontinued patients
- Geographic & age expansion
- Patient growth

**RP view with new CF triple**

**$13bn+**

**Reflects 50-75% conversion from Trikafta to new CF triple**

NPV impact of potential downside scenarios are estimated to be $1-$2 per share

**RP** is entitled to royalties on CF products that arose out of the collaboration between Vertex and the Cystic Fibrosis Foundation. Royalties are not tied to patents.

---

4. Indicates date applicable product when generic competition is expected to enter the market.

RP is entitled to royalties on CF products that arose out of the collaboration between Vertex and the Cystic Fibrosis Foundation. Royalties are not tied to patents.
Long-term growth powered by consistent portfolio refreshment

Adjusted Cash Receipts evolution through 2030\(^{(1)}\)

(2030 growth target provided at May 2022 Investor Day)

10\%+ CAGR

\(\text{(}$200-\text{}$300m)\)

Compared to status quo of Trikafta alone

\(\text{~}$4,700+\)

2030 target

Drivers:
+ Base business
+ Future investments

\(\text{~}$4,700+\)

CF downside scenarios

Adjusted Cash Receipts evolution through 2030\(^{(1)}\)

Continued execution on strategy

- **Power of business model**
  - Transactions since 2020 expected to add ~$1bn in ACR by 2025

- **Future capital deployment**
  - Tracking to meet or exceed capital deployment guidance of $10-$12 billion from 2022 through 2026

- **Increased diversification**
  - The CF franchise will become a smaller portion of the business as we continue to scale
  - CF is ~30\% of 2022 ACR prior to Biohaven payments and expected to decline to teens % of 2030 ACR

Expect to deliver \(10\%+\) top-line CAGR over the decade under downside CF scenarios

\[\text{Compared to status quo of Trikafta alone}\]

\[\text{~}$4,700+\]

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)

\(\text{~}$4,700+\)
Well positioned in evolving interest rate environment

**Existing capital structure**

- Long duration, low-cost debt an underappreciated asset
  - Fixed weighted-average coupon of ~2.5% on $6.3bn of investment grade bonds
  - ~70% of existing bonds due 2030 or later
  - Committed to investment grade rating
  - Revolving credit facility of up to $1.5bn

**Future investments**

- Higher risk-adjusted returns
  - Higher royalty return expectations in response to higher rate environment
  - Maintaining attractive returns above cost of capital with consistent spreads

**Expanding opportunity set**

- Higher partner cost of capital accelerates momentum in royalty funding
Continuing to create value in changing market environment

Lower interest rates (2012-2021)

Returns above cost of capital remain attractive with spreads maintained

Cost of capital: ~3 - 4.5%

Value creation

Unlevered returns (approved products)

~6%

Higher interest rates (2022-today)

Cost of capital: ~5 - 7%

Value creation

Unlevered returns (approved products)

~7-8%

Spreads maintained and larger opportunity set equals greater value creation

1. Transaction purchasing 43% of PTC’s Evrysdi royalty announced July 2020.
2. Transaction purchasing 67% of PTC’s remaining Evrysdi royalty announced October 2023.
3. Illustrative returns reflect a combination of actual results and estimated projected returns for investments from 2012 – 2023 YTD. IRR (or returns) are calculated using total cash outflows and total cash inflows, in each case including royalties, milestones and other cash flows.
Maximizing industry strengths and minimizing challenges

Maximizing
- Exposure to transformative therapies
- Revenue and profit diversification
- Therapeutic area breadth
- Long weighted average portfolio duration
- Consistent and sustainable growth
- Management team continuity
- Shareholder alignment
- Opportunity - entire R&D ecosystem is our pipeline

Minimizing
- Early-stage development risk
- R&D and SG&A cost base
- Therapeutic area bias
- Highly competitive business development
- Late-stage clinical binary risk
A unique way to invest in biopharma

<table>
<thead>
<tr>
<th></th>
<th>Royalty Pharma</th>
<th>Large biopharma(1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Growth</strong></td>
<td>2020-2030 top-line(2) CAGR</td>
<td>10% or more(2)</td>
</tr>
<tr>
<td><strong>Scale</strong></td>
<td>Number of blockbusters(4)</td>
<td>15</td>
</tr>
<tr>
<td><strong>Cost of capital</strong></td>
<td>Estimated WACC</td>
<td>~7-8%</td>
</tr>
<tr>
<td><strong>Risk</strong></td>
<td>Stage of development</td>
<td>Post proof-of-concept to approved</td>
</tr>
<tr>
<td><strong>Return</strong></td>
<td>Historical return on investments(5)</td>
<td>Consistent low teens IRR</td>
</tr>
<tr>
<td><strong>Income</strong></td>
<td>Dividend yield</td>
<td>~3%</td>
</tr>
<tr>
<td><strong>Ownership</strong></td>
<td>Management % ownership of FDSO</td>
<td>16%(6)</td>
</tr>
</tbody>
</table>

CAGR: compound annual growth rate; WACC: weighted average cost of capital; IRR: internal rate of return; FDSO: fully diluted shares outstanding

1. Consists of Eli Lilly, Johnson & Johnson, Merck, Pfizer, AbbVie, Bristol Myers Squibb, Gilead, Amgen, Biogen, Vertex, Regeneron, Roche, Novartis, GSK, Sanofi, Novo Nordisk and AstraZeneca.
2. Top-line refers to Royalty Pharma’s Adjusted Cash Receipts and includes future investments. Royalty Pharma growth target provided at May 2022 Investor Day. See slide 63 for definitions.
4. Calculated based on 2022 end market sales and excludes products tied to recently expired royalties.
5. Historical return on investments for Royalty Pharma is from 2012 to Q3 2023; IRR (or returns) are calculated using total cash outflows and total cash inflows, in each case including royalties, milestones and other cash flows. Biopharma returns on investments in business development, M&A and R&D.
6. Represents Named Executive Officer (NEO) ownership reported by CapIQ for Large biopharma; Royalty Pharma NEO ownership as disclosed in 2022 proxy filing.
A simple investment proposition in a highly complex industry

Successful biopharma investing is extremely complex

**Royalty Pharma** offers a simple solution

- Efficient business of collecting share of top-line revenues on leading products
- Strong track record of product selection
- Rigorous diligence processes
- Highly diversified portfolio
- Minimal binary clinical risk
- Proven ability to replenish portfolio
Appendix
## Detailed calculation assumptions for CF triple scenarios

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Product</th>
<th>Blended Royalty⁽¹⁾</th>
<th>Sales Split</th>
<th>Franchise Sales</th>
<th>Royalty Receipts</th>
<th>NCI %</th>
<th>2030 ACR from CF⁽³⁾</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status quo</strong></td>
<td>Trikafta</td>
<td>~9%</td>
<td>100%</td>
<td>~$11.5bn⁽²⁾</td>
<td>~$1,050m</td>
<td>(13%)</td>
<td>~$900m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RP Position:</strong></td>
<td>Trikafta</td>
<td>~9%</td>
<td>50%</td>
<td>$13bn+</td>
<td>~$1,100m</td>
<td>(13%)</td>
<td>~$950m</td>
</tr>
<tr>
<td>New CF Triple</td>
<td></td>
<td>~8%</td>
<td>50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total Blended</td>
<td>~9%</td>
<td>100%</td>
<td>$13bn+</td>
<td>~$1,050m</td>
<td>(14%)</td>
<td>~$900m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>New CF Triple</strong></td>
<td>Trikafta</td>
<td>~9%</td>
<td>25%</td>
<td>$13bn+</td>
<td>~$1,050m</td>
<td>(14%)</td>
<td>~$900m</td>
</tr>
<tr>
<td>(deuterated ivacaftor is not royalty bearing)</td>
<td></td>
<td>~8%</td>
<td>75%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total Blended</td>
<td>~8%</td>
<td>100%</td>
<td>$13bn+</td>
<td>~$1,050m</td>
<td>(14%)</td>
<td>~$900m</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>New CF Triple</strong></td>
<td>Trikafta</td>
<td>~9%</td>
<td>25%</td>
<td>$13bn+</td>
<td>~$700m</td>
<td>(17%)</td>
<td>~$600m</td>
</tr>
<tr>
<td>(deuterated ivacaftor is royalty bearing)</td>
<td></td>
<td>~4%</td>
<td>75%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total Blended</td>
<td>~7%</td>
<td>100%</td>
<td>$13bn+</td>
<td>~$700m</td>
<td>(17%)</td>
<td>~$600m</td>
</tr>
</tbody>
</table>

Reflects 50-75% conversion from Trikafta to new triple

**Calculations may not tie due to rounding**

**Notes:**
- RP: Royalty Pharma; CF: Cystic Fibrosis; ACR: Adjusted Cash Receipts; NCI: Non-Controlling Interests.
- 1. Vanzacaftor royalty rates based on statements by Vertex.
- 2. Vertex-collated consensus derived from Visible Alpha.
- 3. For the CF royalty, NCI equates to (17.6%) of royalty receipts on annual royalty bearing sales up to $5.8bn and (8.8%) of the annual royalty bearing sales above $5.8bn. For products with multiple components, royalty bearing sales are allocated equally to each of the active pharmaceutical ingredients.
- 4. ACR figures shown are net of estimated distributions to legacy non-controlling interests (NCI). Cash royalty receipts are received on a one-quarter lag, so 2030 ACR reflects Q4 2029 – Q3 2030 reported sales.
## Biohaven partnership blossoms with additional transactions

<table>
<thead>
<tr>
<th>Date</th>
<th>June 2018⁽¹⁾</th>
<th>December 2018</th>
<th>March 2019⁽²⁾</th>
<th>August 2020⁽³⁾</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding type</td>
<td>Royalty and common equity</td>
<td>Common equity</td>
<td>Preferred equity</td>
<td>Royalty and Launch capital</td>
</tr>
<tr>
<td>Purpose</td>
<td>Support Nurtec ODT Phase 3 development</td>
<td>Support Nurtec ODT development and FDA filing</td>
<td>Priority review voucher to accelerate Nurtec ODT launch</td>
<td>Pipeline funding and commercialization support</td>
</tr>
<tr>
<td>Details</td>
<td>$100m royalty (2.1% royalty on Nurtec ODT and zavegepant sales up to $1.5bn and 1.5% for sales &gt;$1.5bn) $50m equity investment (at $45 per share)</td>
<td>$37m equity investment (at $37 per share)</td>
<td>$125m preferred equity (upfront) Up to $75m preferred equity (on Nurtec ODT FDA approval – optional, not drawn)</td>
<td>$250m royalty R&amp;D funding (0.4% royalty on Nurtec ODT, up to 3% zavegepant royalty, and potential zavegepant milestones) $200m launch capital</td>
</tr>
<tr>
<td>Total investment</td>
<td>$150m</td>
<td>$37m</td>
<td>Up to $200m</td>
<td>Up to $450m</td>
</tr>
</tbody>
</table>

Up to ~$835m in total funding across multiple deals to accelerate Biohaven’s innovative migraine therapies to patients

Nurtec ODT – one of the strongest recent launches in biopharma

- Positive pivotal Nurtec ODT efficacy studies
- Positive Nurtec ODT long-term safety study
- FDA approval of Nurtec ODT for acute migraine
- Positive Phase 3 Nurtec ODT migraine prevention study
- FDA approval of Nurtec ODT for migraine prevention
- Biohaven Ex-U.S. collaboration with Pfizer
- Pfizer to acquire Biohaven

Encouraging oral CGRP volumes

Successful Nurtec ODT launch in US

Nurtec ODT global net revenue ($ in millions)

> $6bn

CGRP: calcitonin gene-related peptide

Biohaven acquisition accelerates Royalty Pharma returns

- Pfizer, a strong global marketer, is positioned to maximize the potential of Nurtec ODT and zavegepant
  - Doubling number of sales representatives detailing Nurtec
- Acquisition\(^{(2)}\) accelerated Royalty Pharma’s returns on common and preferred equity
- No impact on Royalty Pharma’s royalty terms, which will provide long-duration cash flows
- Entitled to milestones of up to 1.9 to 2.95x funded amount of $250m related to zavegepant\(^{(3)}\)
  - Pre-payment option may accelerate returns

Potential ~1.8x cash return by H1 2023 with further upside from continuing royalties and additional milestones

1. Royalty Pharma Form 8-K, May 11, 2022. 2. Acquisition of Biohaven by Pfizer closed in October 2022. 3. Royalty Pharma received a total success-based milestone payment of $475m, or 1.9x the funded amount, related to its first regulatory approval in migraine. Incremental payments of up to 1.05x the funded amount could be triggered by certain additional regulatory approvals. 4. Total inflows consist of common equity, preferred equity and estimated royalties received from Nurtec ODT through H1 2023 based on consensus estimates.
**Important milestones expected over the next year**

### Select recent and expected upcoming events

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Expected Year</th>
<th>Quarter</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cabometyx, Tecentriq Phase 3 results for mCRPC (CONTACT-02)</td>
<td>2023</td>
<td>Q3</td>
</tr>
<tr>
<td>Cabometyx, Opdivo, Yervoy Phase 3 OS results for 1L renal cell carcinoma (COSMIC 313)</td>
<td>2023</td>
<td>Q4</td>
</tr>
<tr>
<td>Tremfya Phase 3 results for Crohn’s disease</td>
<td>2023</td>
<td>Q3</td>
</tr>
<tr>
<td>Aficamten Phase 3 results for obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM)</td>
<td>2023</td>
<td>Q4</td>
</tr>
<tr>
<td>Pelabresib, Jakafi Phase 3 results for myelofibrosis (MANIFEST-2)</td>
<td>2023</td>
<td>Q3</td>
</tr>
<tr>
<td>Seltorexant Phase 3 results for major depressive disorder with insomnia symptoms</td>
<td>2023</td>
<td>Q3</td>
</tr>
<tr>
<td>KarXT Phase 3 results for schizophrenia adjunctive (ARISE)</td>
<td>2023</td>
<td>Q3</td>
</tr>
<tr>
<td>Trodelvy Phase 3 results for 2-3L non-small cell lung cancer (EVOKE-01)</td>
<td>2023</td>
<td>Q3</td>
</tr>
<tr>
<td>MK-8189 Phase 2b results for schizophrenia</td>
<td>2023</td>
<td>Q4</td>
</tr>
<tr>
<td><strong>Regulatory</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trodelvy EC decision in pre-treated HR+/HER2- metastatic breast cancer</td>
<td>2023</td>
<td></td>
</tr>
<tr>
<td>Xtandi, leuprolide FDA decision in non-metastatic castration sensitive prostate cancer</td>
<td>2023</td>
<td></td>
</tr>
<tr>
<td>KarXT FDA decision in schizophrenia</td>
<td>2023</td>
<td></td>
</tr>
</tbody>
</table>

---

mCRPC: metastatic castration-resistant prostate cancer; OS: overall survival; FDA: Food & Drug Administration; EC: European Commission

---

Potential royalties on ~40 projects in late-stage development

- **Phase 2**
  - MK-8189: Schizophrenia
  - trontinemb: Alzheimer’s disease
  - aficamten: oHCM
  - pembrolizumab: metastatic NSCLC
  - seltorexant: AD with agitation/aggression
  - Skytrofa: Turner syndrome
  - Tazverik (+ hormonotherapy): mCRPC
  - Tremfya: Giant cell arteritis
  - Trodelvy: Lung, HNSCC and endometrial
  - Trodelvy (+ combinations): 1L mUC

- **Phase 3**
  - aficamten: oHCM
  - pelacarsen: Cardiovascular disease
  - olpasiran: Cardiovascular disease
  - Imbruvica: 1L Follicular lymphoma
  - Tremfya: Ulcerative colitis
  - Tremfya: Crohn’s disease
  - Trodelvy: 1L TNBC (PD-L1-)
  - Trodelvy: 2L+ mUC
  - Trodelvy: ( + pembrolizumab): 1L TNBC (PD-L1+)
  - Trodelvy: ( + pembrolizumab): 2L mNSCLC
  - Trodelvy: ( + pembrolizumab): Adjuvant TNBC
  - Trodelvy: ( + pembrolizumab): 1L mNSCLC
  - Cabometyx (+ PD1): 1L metastatic RCC

- **Registration**
  - olpasiran: Cardiovascular disease
  - olpasiran: 1L Myelofibrosis
  - ampreloxetine: Symptomatic nOH in MSA
  - seltorexant: MDD w/insomnia symptoms
  - pelacarsen: 1L Myelofibrosis
  - pelacarsen: Blood cancer, solid tumors
  - olpasiran: Cardiovascular disease
  - olpasiran: Schizophrenia (adjunctive)

- **New molecular entity**
  - Rare disease: Alzheimer’s disease
  - Immunology: oHCM
  - Cancer: Cancer
  - Neurology: Neurology
  - Cardio-Metabolic: Cardio-Metabolic
  - Immunology: Immunology

HNSCC: head and neck squamous cell carcinoma; mCRPC: metastatic castration-resistant prostate cancer; AD: Alzheimer’s disease; mUC: metastatic urothelial carcinoma; NSCLC: non-small-cell lung carcinoma; oHCM: obstructive hypertrophic cardiomyopathy; mTNBC: metastatic triple negative breast cancer; TNBC: triple negative breast cancer; mBC: metastatic breast cancer; nOH: neurogenic orthostatic hypotension; MSA: multiple system atrophy; RCC: renal cell carcinoma; NET: neuroendocrine tumors; nHCM: non-obstructive hypertrophic cardiomyopathy; MDD: major depressive disorder; PsA: Psoriatic Arthritis; GHD: growth hormone deficiency; nmCSPC: non-metastatic castration sensitive prostate cancer.

1. EVOKE-02. 2. EVOKE-03. 3. High risk localized advanced prostate cancer prior to radical prostatectomy. 4. High risk localized advanced prostate cancer receiving primary radiation therapy. 5. EVOKE-03.
## Royalty Pharma non-GAAP financial measures

<table>
<thead>
<tr>
<th>$ in millions</th>
<th>FY 2022</th>
<th>FY 2021</th>
<th>FY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Royalty receipts</td>
<td>3,231</td>
<td>2,609</td>
<td>2,344</td>
</tr>
<tr>
<td>Distributions to non-controlling interests</td>
<td>(442)</td>
<td>(480)</td>
<td>(544)</td>
</tr>
<tr>
<td><strong>Adjusted Cash Receipts (non-GAAP)</strong>(1)</td>
<td>2,789</td>
<td>2,129</td>
<td>1,800</td>
</tr>
<tr>
<td>Payments for operating and professional costs</td>
<td>(223)</td>
<td>(185)</td>
<td>(180)</td>
</tr>
<tr>
<td><strong>Adjusted EBITDA (non-GAAP)</strong>(1)</td>
<td>2,566</td>
<td>1,944</td>
<td>1,621</td>
</tr>
<tr>
<td>Development-stage funding payments – ongoing</td>
<td>(2)</td>
<td>(7)</td>
<td>(20)</td>
</tr>
<tr>
<td>Development-stage funding payments – upfront &amp; milestones</td>
<td>(175)</td>
<td>(193)</td>
<td>(6)</td>
</tr>
<tr>
<td>Interest paid, net</td>
<td>(145)</td>
<td>(127)</td>
<td>(95)</td>
</tr>
<tr>
<td>Investments in equity method investees</td>
<td>(10)</td>
<td>(35)</td>
<td>(40)</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>(16)</td>
<td>10</td>
</tr>
<tr>
<td>Contributions from non-controlling interests – R&amp;D</td>
<td>1</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td><strong>Adjusted Cash Flow (non-GAAP)</strong>(1)</td>
<td>2,235</td>
<td>1,573</td>
<td>1,477</td>
</tr>
</tbody>
</table>

---

1. Amounts may not add due to rounding.

Refer to slide 63 for definitions. Refer to Royalty Pharma’s Current Reports on Form 8-K filed with the SEC on November 8, 2023 for additional discussion.
### GAAP to non-GAAP reconciliation – Adjusted Cash Receipts

<table>
<thead>
<tr>
<th>$ in millions</th>
<th>FY 2022</th>
<th>FY 2021</th>
<th>FY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash provided by operating activities (GAAP)</td>
<td>2,144</td>
<td>2,018</td>
<td>2,035</td>
</tr>
<tr>
<td>Adjustments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds from available for sales debt securities</td>
<td>542</td>
<td>63</td>
<td>3</td>
</tr>
<tr>
<td>Distributions from equity method investees – investing</td>
<td>-</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>Interest paid, net</td>
<td>145</td>
<td>127</td>
<td>95</td>
</tr>
<tr>
<td>Development-stage funding payments – ongoing</td>
<td>2</td>
<td>7</td>
<td>20</td>
</tr>
<tr>
<td>Development-stage funding payments – upfront and milestones</td>
<td>175</td>
<td>193</td>
<td>6</td>
</tr>
<tr>
<td>Payments for operating and professional costs</td>
<td>223</td>
<td>185</td>
<td>180</td>
</tr>
<tr>
<td>Termination payments on derivative instruments</td>
<td>-</td>
<td>16</td>
<td>35</td>
</tr>
<tr>
<td>Distributions to non-controlling interests</td>
<td>(442)</td>
<td>(480)</td>
<td>(544)</td>
</tr>
<tr>
<td>Derivative collateral received, net</td>
<td>-</td>
<td>-</td>
<td>(45)</td>
</tr>
<tr>
<td><strong>Adjusted Cash Receipts (non-GAAP)</strong>(1)</td>
<td>2,789</td>
<td>2,129</td>
<td>1,800</td>
</tr>
</tbody>
</table>

Amounts may not add due to rounding.

1. Refer to slide 63 for definitions. Refer to Royalty Pharma’s Current Reports on Form 8-K filed with the SEC on November 8, 2023 for additional discussion.
GAAP to non-GAAP reconciliation – Adjusted EBITDA

<table>
<thead>
<tr>
<th>$ in millions</th>
<th>FY 2022</th>
<th>FY 2021</th>
<th>FY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash provided by operating activities (GAAP)</td>
<td>2,144</td>
<td>2,018</td>
<td>2,035</td>
</tr>
<tr>
<td>Adjustments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds from available for sales debt securities</td>
<td>542</td>
<td>63</td>
<td>3</td>
</tr>
<tr>
<td>Distributions from equity method investees – investing</td>
<td>-</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>Interest paid, net</td>
<td>145</td>
<td>127</td>
<td>95</td>
</tr>
<tr>
<td>Development-stage funding payments – ongoing</td>
<td>2</td>
<td>7</td>
<td>20</td>
</tr>
<tr>
<td>Development-stage funding payments – upfront and milestones</td>
<td>175</td>
<td>193</td>
<td>6</td>
</tr>
<tr>
<td>Termination payments on derivative instruments</td>
<td>-</td>
<td>16</td>
<td>35</td>
</tr>
<tr>
<td>Distributions to non-controlling interests</td>
<td>(442)</td>
<td>(480)</td>
<td>(544)</td>
</tr>
<tr>
<td>Derivative collateral received, net</td>
<td>-</td>
<td>-</td>
<td>(45)</td>
</tr>
<tr>
<td>Adjusted EBITDA (non-GAAP)(1)</td>
<td>2,566</td>
<td>1,944</td>
<td>1,621</td>
</tr>
</tbody>
</table>

Amounts may not add due to rounding.

1. Refer to slide 63 for definitions. Refer to Royalty Pharma’s Current Reports on Form 8-K filed with the SEC on November 8, 2023 for additional discussion.
## GAAP to non-GAAP reconciliation – Adjusted Cash Flow

<table>
<thead>
<tr>
<th>$ in millions</th>
<th>FY 2022</th>
<th>FY 2021</th>
<th>FY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net cash provided by operating activities (GAAP)</td>
<td>2,144</td>
<td>2,018</td>
<td>2,035</td>
</tr>
<tr>
<td>Adjustments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds from available for sales debt securities</td>
<td>542</td>
<td>63</td>
<td>3</td>
</tr>
<tr>
<td>Distributions from equity method investees – investing</td>
<td>-</td>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>Distributions to non-controlling interests</td>
<td>(442)</td>
<td>(480)</td>
<td>(544)</td>
</tr>
<tr>
<td>Investments in equity method investees</td>
<td>(10)</td>
<td>(35)</td>
<td>(40)</td>
</tr>
<tr>
<td>Contributions from non-controlling interests – R&amp;D</td>
<td>1</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Adjusted Cash Flow (non-GAAP)(1)</td>
<td>2,235</td>
<td>1,573</td>
<td>1,477</td>
</tr>
</tbody>
</table>

Amounts may not add due to rounding.

1. Refer to slide 63 for definitions. Refer to Royalty Pharma’s Current Reports on Form 8-K filed with the SEC on November 8, 2023 for additional discussion.
Footnotes

(1) To aid in comparability, growth in 2020 is calculated based on pro forma 2019 results, which adjusts certain cash flow line items as if Royalty Pharma’s Reorganization Transactions (as described in the Company’s final prospectus filed with the SEC on June 17, 2020 ("Prospectus") and its initial public offering ("IPO") had taken place on January 1, 2019. The most significant difference between the pro forma and reported figures is the new non-controlling interests that resulted from the Reorganization Transactions. The new contractual non-controlling interests arose in the Reorganization Transactions that results in a higher distribution to non-controlling interests on a pro forma basis as compared to prior historical periods. Less material differences also arise in Royalty receipts for other products as well as Payments for operating and professional costs, Interest paid, net and in the payments associated with our former interest rate swap contracts.

(2) Adjusted Cash Receipts is a measure calculated with inputs directly from the statements of cash flows and includes (1) royalty receipts by product: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from equity method investees, plus (2) Proceeds from available for sale debt securities, less (1) Distributions to non-controlling interests, which represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to our historical non-controlling interests related to the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust (RPSFT). See the Company’s Annual Report on Form 10-K filed with the SEC on February 15, 2023 and refer to Royalty Pharma’s Current Reports on Form 8-K filed with the SEC on November 8, 2023 for additional discussion. See GAAP to Non-GAAP reconciliation in the Company’s current report on Form 8-K dated November 8, 2023.

(3) Adjusted EBITDA is important to lenders and is defined under the credit agreement as Adjusted Cash Receipts less payments for operating and professional costs. Operating and professional costs are comprised of Payments for operating and professional costs from the statements of cash flows. See GAAP to Non-GAAP reconciliation in the Company’s current report on Form 8-K dated November 8, 2023.

(4) Adjusted Cash Flow is defined as Adjusted EBITDA less (1) Development-stage funding payments - ongoing, (2) Development-stage funding payments - upfront and milestones, (3) Interest paid, net of Interest received, (4) Investments in equity method investees and (5) Other (including Derivative collateral posted, net of Derivative collateral received and Termination payments on derivative instruments) plus (1) Contributions from non-controlling interests- R&D, all directly reconcilable to the statements of cash flows. See GAAP to Non-GAAP reconciliation in the Company’s current report on Form 8-K dated November 8, 2023.

Financial Guidance footnote

(5) Royalty Pharma has not reconciled its non-GAAP 2022 guidance to the most directly comparable GAAP measure, cash flow from operations, at this time due to the inherent difficulty in accurately forecasting and quantifying certain amounts that are necessary for such reconciliation, including, primarily, payments for operating and professional costs, distributions from equity method investees, and interest received. The Company is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to project cash flow from operations on a GAAP basis at this time.

Long-term Outlook footnote

(6) Royalty Pharma’s long-term outlook is based on its most up-to-date view on its prospects as of May 17, 2022. This long-term outlook assumes no major unforeseen adverse events subsequent to the date of this presentation. Growth outlook includes future royalty acquisitions. Furthermore, Royalty Pharma may amend its long-term outlook in the event it engages in new royalty transactions. See the information on slide 3 “Forward Looking Statements & Non-GAAP Financial Information,” for factors that may impact the long-term outlook.